Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | L3MBTL3 | Q96JM7 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5701961 | 1.00 | CA2 (0.54) | CA2ALDH1A1TDP1L3MBTL1ACHE | |
| SCHEMBL5701920 | 1.00 | CA2 (0.54) | CA2ALDH1A1TDP1L3MBTL1ACHE | |
| SCHEMBL7879782 | 0.98 | CA2 (0.52) | CA2ALDH1A1TDP1L3MBTL1ACHE | |
| Water SCHEMBL7879777 | 0.96 | CA2 (0.51) | CA2ALDH1A1TDP1L3MBTL1ACHE | |
| SCHEMBL5702058 | 0.90 | HPGD (0.54) | CA2ALDH1A1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL5702038 | 0.90 | HPGD (0.54) | CA2ALDH1A1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL13230 | 0.89 | CA2 (0.67) | CA2ALDH1A1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL13229 | 0.89 | CA2 (0.67) | CA2ALDH1A1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL28789388 | 0.89 | CA2 (0.67) | CA2ALDH1A1TDP1L3MBTL1SMN1; SMN2 | |
| SCHEMBL3575904 | 0.88 | TDP1 (0.66) | CA2ALDH1A1TDP1L3MBTL1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1003885-A1 | MICROORGANISM AND ESTERASE OBTAINED THEREFROM | Chirotech Technology Limited (GB) | 2000-05-31 | — | — | EP | claimed |
| WO-1999004015-A1 | MICROORGANISM AND ESTERASE OBTAINED THEREFROM | CHIROTECH TECHNOLOGY LIMITED (GB) | 1999-01-28 | — | — | WO | claimed |
| EP-2576803-B1 | PREPARATION OF (3aS,7aR)-HEXAHYDROISOBENZOFURAN-1(3H)-ONE BY CATALYZED BIOLOGICAL RESOLUTION OF DIMETHYL CYCLOHEXANE-1,2-DICARBOXYLATE | BGP PRODUCTS OPERATIONS GMBH (CH) | 2019-07-10 | — | — | EP | disclosed |
| EP-0912755-B1 | THE BIORESOLUTION OF N-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | ASTRAZENECA AB (SE) | 2003-06-04 | — | — | EP | disclosed |
| EP-0970049-B1 | PROCESS FOR THE PRODUCTION OF ENANTIOMERICALLY ENRICHED N-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | ASTRAZENECA AB (SE) | 2002-06-05 | — | — | EP | disclosed |
| US-6333418-B1 | Cyclisation process | ASTRAZENECA AB (SE) | 2001-12-25 | — | — | US | disclosed |
| US-6313315-B1 | RESOLUTION; ENANTIOMORPHIC PURIFICATION; CRYSTALLIZATION IN SOLVENT | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-11-06 | — | — | US | disclosed |
| EP-1098876-A1 | CYCLISATION PROCESS | AstraZeneca AB (SE) | 2001-05-16 | — | — | EP | disclosed |
| EP-1057810-A1 | Method for producing n-protected-azetidine-2-carboxylic acids | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2000-12-06 | — | — | EP | disclosed |
| US-6136591-A | Bioresolution of N-acylazetidine-2-carboxylic acids | ASTRA AB (SE) | 2000-10-24 | — | — | US | disclosed |
| EP-1003885-A1 | MICROORGANISM AND ESTERASE OBTAINED THEREFROM | Chirotech Technology Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| EP-1003885-A1 | MICROORGANISM AND ESTERASE OBTAINED THEREFROM | Chirotech Technology Limited (GB) | 2000-05-31 | — | — | EP | disclosed |
| US-6054594-A | Process for the production of enantiomerically enriched N-acylazetidine-2-carboxylic acids | ASTRA AB (SE) | 2000-04-25 | — | — | US | disclosed |
| WO-2000003982-A1 | CYCLISATION PROCESS | ASTRAZENECA AB (SE) | 2000-01-27 | — | — | WO | disclosed |
| EP-0970049-A1 | PROCESS FOR THE PRODUCTION OF ENANTIOMERICALLY ENRICHED $i(N)-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | Astra Aktiebolag (SE) | 2000-01-12 | — | — | EP | disclosed |
| EP-0912755-A1 | THE BIORESOLUTION OF N-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | Astra Aktiebolag (SE) | 1999-05-06 | — | — | EP | disclosed |
| WO-1999004015-A1 | MICROORGANISM AND ESTERASE OBTAINED THEREFROM | CHIROTECH TECHNOLOGY LIMITED (GB) | 1999-01-28 | — | — | WO | disclosed |
| WO-1999004015-A1 | MICROORGANISM AND ESTERASE OBTAINED THEREFROM | CHIROTECH TECHNOLOGY LIMITED (GB) | 1999-01-28 | — | — | WO | disclosed |
| WO-1998002417-A1 | PROCESS FOR THE PRODUCTION OF ENANTIOMERICALLY ENRICHED N-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | ASTRA AKTIEBOLAG (SE) | 1998-01-22 | — | — | WO | disclosed |
| WO-1998002568-A1 | THE BIORESOLUTION OF N-ACYLAZETIDINE-2-CARBOXYLIC ACIDS | ASTRA AKTIEBOLAG (SE) | 1998-01-22 | — | — | WO | disclosed |